Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. The company operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The company provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals. Zoetis was founded in 1952 and is headquartered in Parsippany, NJ.
Highlights
ZTS's equity is up by 24% year-on-year and by 8% since the previous quarter
Zoetis's EPS has increased by 19% YoY
Zoetis's quick ratio has increased by 41% QoQ but it has decreased by 7% YoY
The debt rose by 19% YoY and by 19% QoQ
The P/E is 17% higher than the last 4 quarters average of 39.5 and 15% higher than the 5-year quarterly average of 40.1
Key stats
What are the main financial stats of ZTS
Market
Shares outstanding
475.14M
Market cap
$74.62B
Enterprise value
$79.12B
Valuations
Price to earnings (P/E)
46.19
Price to book (P/B)
25.01
Price to sales (P/S)
11.77
EV/EBIT
36.49
EV/EBITDA
30.37
EV/Sales
12.48
Earnings
Revenue
$6.34B
EBIT
$2.17B
EBITDA
$2.61B
Free cash flow
$1.46B
Per share
EPS
$3.4
Free cash flow per share
$3.06
Book value per share
$6.28
Revenue per share
$13.34
TBVPS
$18.21
Balance sheet
Total assets
$13.07B
Total liabilities
$10.08B
Debt
$7.85B
Equity
$2.98B
Working capital
$4.47B
Liquidity
Debt to equity
2.63
Current ratio
3.47
Quick ratio
2.39
Net debt/EBITDA
1.73
Margins
EBITDA margin
41.1%
Gross margin
69.7%
Net margin
25.5%
Operating margin
34.2%
Efficiency
Return on assets
13.6%
Return on equity
58.2%
Return on invested capital
20.7%
Return on capital employed
19.3%
Return on sales
34.2%
Dividend
Dividend yield
0.49%
DPS
$0.76
Payout ratio
22.5%
ZTS stock price
How has the Zoetis stock price performed over time
Financial performance
How have Zoetis's revenue and profit performed over time
Revenue
$6.34B
Gross profit
$4.42B
Operating income
$2.17B
Net income
$1.62B
Gross margin
69.7%
Net margin
25.5%
The net income has grown by 18% YoY
Zoetis's operating income has increased by 14% YoY
The net margin rose by 12% YoY
The gross profit has grown by 9% YoY
Valuation
What is Zoetis stock price valuation
P/E
46.19
P/B
25.01
P/S
11.77
EV/EBIT
36.49
EV/EBITDA
30.37
EV/Sales
12.48
Zoetis's EPS has increased by 19% YoY
The P/E is 17% higher than the last 4 quarters average of 39.5 and 15% higher than the 5-year quarterly average of 40.1
The stock's price to book (P/B) is 28% more than its 5-year quarterly average of 19.6 and 14% more than its last 4 quarters average of 21.9
ZTS's equity is up by 24% year-on-year and by 8% since the previous quarter
ZTS's price to sales (P/S) is 68% higher than its 5-year quarterly average of 7.0 and 21% higher than its last 4 quarters average of 9.7
ZTS's revenue is up by 4.9% YoY
Efficiency
How efficient is Zoetis business performance
ZTS's ROIC is up by 10% YoY
Zoetis's return on sales has increased by 9% YoY
ZTS's return on assets is up by 6% year-on-year but it is down by 4.2% since the previous quarter
The company's return on equity fell by 4.7% QoQ and by 4.4% YoY
Dividends
What is ZTS's dividend history
DPS
$0.76
Dividend yield
0.49%
Payout ratio
22.5%
Recent dividends
Financial health
How did Zoetis financials performed over time
ZTS's total assets is 30% greater than its total liabilities
Zoetis's quick ratio has increased by 41% QoQ but it has decreased by 7% YoY
The company's current ratio rose by 25% QoQ but it fell by 17% YoY
The debt is 163% higher than the equity
ZTS's equity is up by 24% year-on-year and by 8% since the previous quarter
The debt rose by 19% YoY and by 19% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated
quarterly, unless otherwise specified.